Plasma rich in growth factors membrane for macular holes in eyes with pathological myopia without peeling of internal limiting membrane

Background Myopic macular holes (MH) present a significant surgical challenge due to their low closure rates and poor visual prognosis. Conventional approaches frequently require internal limiting membrane (ILM) peeling, which adds surgical complexity and potential risks. Plasma rich in growth factors membrane (PRGFm) has emerged as a biological scaffold that promotes retinal repair and may facilitate MH closure without ILM manipulation. This study aims to evaluate the usefulness of PRGFm in improving closure of myopic macular holes without peeling of the ILM. Methods Observational study of a consecutive case series. Pathological myopia patients with MH. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT) data, anatomic closure rates were documented. Results 7 patients who met the inclusion criteria were enrolled. Median follow-up was 6 months. The MH before surgery had a median size of 810 micrometers, most patients had a BCVA of counting fingers (CF) (2.0 logMAR). Complete macular hole closure was achieved in all cases, and median BCVA was 20/100 (0.7 logMAR). No complications related to PRGFm were found. Conclusion PRGFm is a valuable option for the treatment of MH in pathologic myopic eyes. Its application promotes tissue regeneration and facilitates anatomical closure. The technique is reproducible and does not require manipulation of the internal limiting membrane.